The AJMC® Immuno-Oncology compendium is a comprehensive resource for clinical news and expert insights for treatments that utilize the body's immune system to fight cancer, such as immune checkpoint inhibitors and chimeric antigen receptor T-cell therapies.
May 4th 2024
Authors discuss the merits of using a pair of immunotherapy treatments aimed at separate targets.
Pharma Giants to Collaborate on Immuno-oncology Regimens
January 13th 2015Merck and Eli Lilly have entered an agreement to collaborate on clinical trials to evaluate the former's recently approved PD-1 inhibitor, Keytruda (pembrolizumab) in combination with Lilly's oncology agents in several clinical trials targeting multiple tumor types.
Read More